Crucell subsidiary ends animal testing
This article was originally published in Scrip
Executive Summary
Crucell's Swiss subsidiary Berna Biotech is to close its animal testing facility in Bern, Switzerland, after successfully completing its 3R programme – to Reduce, Refine and Replace all animal testing. Crucell acquired Berna Biotech in 2006 and all of the subsidiary's tests have now been replaced by in vitro assays and any products that were absolutely dependent on animal testing are to be discontinued. The closure of the biotech facility will negatively affect only a few of Crucell's employees as most will be relocated to other departments in its Bern offices, the company said.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.